{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:00:32Z","timestamp":1773154832082,"version":"3.50.1"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100016912","name":"MSD France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Doravirine, the most recent NNRTI, may advantageously replace etravirine in virally suppressed PWH. We evaluated the tolerance and efficacy of doravirine-based ART following a switch from etravirine-based ART.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>SWEED is a national, multicentre, retrospective, observational study including adults with HIV-1 and plasma viral load (pVL) &amp;lt;50\u2005copies\/mL on etravirine-based ART, who switched to doravirine-based ART (same number of associated drugs) from 09\/01\/2019 in 10 French hospitals. The primary outcome was virological failure (VF: confirmed pVL \u226550\u2005copies\/mL or single pVL \u226550 with ART change) at week 48 (W48). Secondary outcomes included rates of strategy success (pVL &amp;lt;50\u2005copies\/mL with no ART change) and treatment discontinuations due to side effects, and changes in CD4 counts and weight.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 109 participants (79% men; median age 59\u2005years), median ART duration was 25\u2005years, with 13\u2005years of sustained viral suppression. Prior NNRTI failure was documented in 41% of participants, and 46% had resistance mutations to at least one NNRTI. ART consisted of 2-drug (53%) and 3-drug (42%) combinations. Median follow-up was 30\u2005months. One VF occurred by W48 (0.9%, 95%CI: 0.0\u20135.0); viral suppression was regained without ART change. Four patients discontinued doravirine-based ART due to adverse events; strategy success rate was 91.7% (95% CI: 84.9\u201396.2) at W48. No significant changes in CD4 counts and weight were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Doravirine-based ART maintained virological suppression in PWH switching from etravirine-based ART, even in presence of prior NNRTI resistance. Its once-daily dosing, favourable safety profile, and minimal drug interactions support its use in long-term ART strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf410","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:29:14Z","timestamp":1760531354000},"source":"Crossref","is-referenced-by-count":1,"title":["Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational study"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0047-0101","authenticated-orcid":false,"given":"Romain","family":"Palich","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Sorbonne University, INSERM 1136, Pierre Louis Epidemiology and Public Health Institute, AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2914-959X","authenticated-orcid":false,"given":"Jade","family":"Ghosn","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Paris Cit\u00e9 University, INSERM 1137, IAME, AP-HP, Bichat Hospital , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Sorbonne University, INSERM 1136, Pierre Louis Epidemiology and Public Health Institute, AP-HP, Saint-Antoine Hospital , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christia","family":"Palacios","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Sorbonne University, INSERM 1136, Pierre Louis Epidemiology and Public Health Institute, AP-HP, Tenon Hospital , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2874-3581","authenticated-orcid":false,"given":"Pierre","family":"Delobel","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Toulouse University Hospital , Toulouse ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Pugliese","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Nice University Hospital , Nice ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-1270","authenticated-orcid":false,"given":"Clotilde","family":"Allavena","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Nantes University Hospital, INSERM CIC1413 , Nantes ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudine","family":"Duvivier","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Paris Cit\u00e9 University, INSERM 1016, Cochin Institute, CNRS 8104, IHU Imagine, AP-HP, Necker-Enfants Malades Hospital, Pasteur Institute, Medical Center , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8268-866X","authenticated-orcid":false,"given":"Firouze","family":"Bani-Sadr","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Reims University Hospital , Reims ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Robineau","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Lille University, EA2694, Tourcoing University Hospital , Tourcoing ,","place":["France"]},{"name":"Pierre Louis Epidemiology and Public Health Institute, Sorbonne University, INSERM 1136 , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmine","family":"Dudoit","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Sorbonne University, INSERM 1136, Pierre Louis Epidemiology and Public Health Institute, AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8785-2460","authenticated-orcid":false,"given":"Duc Hoan","family":"Vu","sequence":"additional","affiliation":[{"name":"Pierre Louis Epidemiology and Public Health Institute, Sorbonne University, INSERM 1136 , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aissata","family":"Kaba","sequence":"additional","affiliation":[{"name":"Pierre Louis Epidemiology and Public Health Institute, Sorbonne University, INSERM 1136 , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2032-4148","authenticated-orcid":false,"given":"Cathia","family":"Soulie","sequence":"additional","affiliation":[{"name":"Virology Department, Sorbonne University, INSERM 1136, Pierre Louis Epidemiology and Public Health Institute, AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Sorbonne University, INSERM 1136, Pierre Louis Epidemiology and Public Health Institute, AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lambert","family":"Assoumou","sequence":"additional","affiliation":[{"name":"Pierre Louis Epidemiology and Public Health Institute, Sorbonne University, INSERM 1136 , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2026011413265258300_dkaf410-B1","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1086\/630210","article-title":"High rate of virologic suppression with raltegravir plus etravirine and darunavir\/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial","volume":"49","author":"Yazdanpanah","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2026011413265258300_dkaf410-B2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/14787210.6.4.427","article-title":"Etravirine for the treatment of HIV infection","volume":"6","author":"Seminari","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026011413265258300_dkaf410-B3","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/S2352-3018(19)30336-4","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial","volume":"7","author":"Molina","year":"2020","journal-title":"Lancet HIV"},{"key":"2026011413265258300_dkaf410-B4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/cid\/ciy540","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate is non-inferior to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial","volume":"68","author":"Orkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026011413265258300_dkaf410-B5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/QAI.0000000000002056","article-title":"Switching to doravirine\/lamivudine\/tenofovir disoproxil fumarate (DOR\/3TC\/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial","volume":"81","author":"Johnson","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026011413265258300_dkaf410-B6","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1128\/AAC.04201-14","article-title":"In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways","volume":"59","author":"Feng","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413265258300_dkaf410-B7","author":"Abdi"},{"key":"2026011413265258300_dkaf410-B8","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/jac\/dkv395","article-title":"Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression","volume":"71","author":"Gantner","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026011413265258300_dkaf410-B9","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1093\/jac\/dky130","article-title":"Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART","volume":"73","author":"Nouchi","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026011413265258300_dkaf410-B10","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/infdis\/jiab413","article-title":"Kinetics of archived M184V mutation in treatment-experienced virally suppressed HIV-infected patients","volume":"225","author":"Palich","year":"2021","journal-title":"J Infect Dis"},{"key":"2026011413265258300_dkaf410-B11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s11904-019-00464-3","article-title":"Aging with HIV","volume":"16","author":"Guaraldi","year":"2019","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2026011413265258300_dkaf410-B12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11904-024-00708-x","article-title":"Metabolic complications associated with use of integrase strand transfer inhibitors (InSTI) for the treatment of HIV-1 infection: focus on weight changes, lipids, glucose and bone metabolism","volume":"21","author":"Savinelli","year":"2024","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2026011413265258300_dkaf410-B13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12981-018-0204-0","article-title":"A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV","volume":"15","author":"Clay","year":"2018","journal-title":"AIDS Res Ther"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf410\/65167665\/dkaf410.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf410\/65167665\/dkaf410.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:26:59Z","timestamp":1768415219000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf410\/8313768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf410","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,11,4]]},"article-number":"dkaf410"}}